Neuroblastoma;Neuroblastom

Urologe - Ausgabe A

Volumn 44, Issue 5, 2005, Pages 543-555

  Simon, T ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Catecholamine metabolites; MYCN; Neuroblastoma; Risk factors; Spontaneous remission

Indexed keywords

CATECHOLAMINE DERIVATIVE; TUMOR MARKER;

CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHILDHOOD CANCER; ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; IMAGING; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE; REVIEW; SCINTIGRAPHY; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION;

ABDOMINAL NEOPLASMS; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 20044369214     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0821-9     Document Type: Review

References (15)

1. Berthold F, Simon T (2005) Clinical presentation. In: Cheung NV, Cohn SL (eds) Neuroblastoma. Springer, Berlin Heidelberg New York, Chap 7, pp 63-85
2. Berthold F, Kremens B, Simon T et al. (2003) Stem cell transplantation vs. maintenance chemotherapy in neuroblastoma: a randomized trial of the GP-OH group (abstract). Med Pediatr Oncol 41: 286
3. Brodeur GM, Pritchard J, Berthold F et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477
4. Guo C, White PS, Weiss MJ et al. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18: 4948-4957
5. Hero B, Graf N, Simon T et al. (2002) Neuroblastoma preoperatively treated as nephroblastoma: does inadequate therapy worsen the prognosis? Klin Padiatr 214: 157-161
6. Maris JM, Weiss MJ, Guo C et al. (2000) Loss of heterozygosity at 1 p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 18: 1888-1899
7. Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173
8. Schilling FH, Spix C, Berthold F et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346: 1047-1053
9. Shimada H, Ambros IM, Dehner LP et al. (1999) Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86: 349-363
10. Shimada H, Ambros IM, Dehner LP et al. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86: 364-372
11. Simon T, Hero B, Faldum A et al. (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22: 3549-3557
12. Simon T, Spitz R, Faldum A et al. (2004) New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26: 791-796
13. Spitz R, Hero B, Westermann F et al. (2002) Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 34: 299-305
14. Spitz R, Hero B, Ernestus K et al. (2003) Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4 s neuroblastoma. Clin Cancer Res 9: 52-58
15. von Schweinitz D, Hero B, Berthold F (2002) The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 12: 402-409